

Financial news for JUNO dated on 2018-03-16: Adam Feuerstein Tweets (2/2): High expectations for BCMA program. Could see more patient relapses. \$CELG JUNO deal a negative.

Financial news for JUNO dated on 2018-03-06: An Eventful February Took Its Toll On TD Ameritrade's Investor Index

Financial news for JUNO dated on 2018-03-06: Investor Movement Index February Summary

Financial news for JUNO dated on 2018-02-21: Celgene Receives Antitrust Clearance for Juno Acquisition

Financial news for JUNO dated on 2018-02-02: Celgene Reports Commencement Of \$87/Share Offer For Juno Therapeutics

Financial news for JUNO dated on 2018-01-31: Attention Biotech Investors: February PDUFA Catalysts Come Calling

Financial news for JUNO dated on 2018-01-30: Gilead Sciences Outlook Brightens; Citi Upgrades

Financial news for JUNO dated on 2018-01-25: Seeing Notable Block Trade In Juno; 1.5M Shares At \$85.77 Below Bid Of \$85.80

Financial news for JUNO dated on 2018-01-25: A Day Trader's Guide To Interpreting Volume

Financial news for JUNO dated on 2018-01-24: Standpoint Research Downgrades Juno Therapeutics to Hold

Financial news for JUNO dated on 2018-01-24: Benzinga's Top Upgrades, Downgrades For January 24, 2018

Financial news for JUNO dated on 2018-01-24: Barclays Downgrades Juno Therapeutics to Equal-Weight

Financial news for JUNO dated on 2018-01-23: Pharma M&A Picks Up Momentum

Financial news for JUNO dated on 2018-01-23: Bluebird Bio Up On Buyout Speculation After Celgene-Juno Deal

Financial news for JUNO dated on 2018-01-23: Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?

Financial news for JUNO dated on 2018-01-23: 8 Biggest Price Target Changes For Tuesday

Financial news for JUNO dated on 2018-01-23: Benzinga's Top Upgrades, Downgrades For January 23, 2018

Financial news for JUNO dated on 2018-01-23: Maxim Group Downgrades Juno Therapeutics to Hold

Financial news for JUNO dated on 2018-01-23: Leerink Downgrades Juno Therapeutics to Market Perform, Raises Price Target to \$87.00

Financial news for JUNO dated on 2018-01-23: HC Wainwright Analyst Raghuram Selvaraju Believes 'Juno Acquisition Bodes Well For Sorrento'; Reiterated Buy Rating, \$30 Price Target

Financial news for JUNO dated on 2018-01-23: SunTrust Robinson Humphrey Downgrades Juno Therapeutics to Hold

Financial news for JUNO dated on 2018-01-23: 38 Biggest Movers From Yesterday

Financial news for JUNO dated on 2018-01-22: Vetr Crowd Downgrades Celgene

Financial news for JUNO dated on 2018-01-22: Mid-Afternoon Market Update: Bioverativ Climbs Following \$105/Share Offer From Sanofi; Recon Technology Shares Drop

Financial news for JUNO dated on 2018-01-22: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for JUNO dated on 2018-01-22: Mid-Day Market Update: Juno Therapeutics Surges On Acquisition News; Sanmina Shares Plummet

Financial news for JUNO dated on 2018-01-22: Mid-Morning Market Update: Markets Gain; Halliburton Profit Beats Estimates

Financial news for JUNO dated on 2018-01-22: The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl

Financial news for JUNO dated on 2018-01-22: Benzinga Pro's 6 Stocks To Watch Today

Financial news for JUNO dated on 2018-01-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for JUNO dated on 2018-01-22: A Peek Into The Markets: U.S. Stock Futures Drop After Government Shutdown

Financial news for JUNO dated on 2018-01-22: Celgene's Acquisition of Juno Therapeutics Worth \$9B

Financial news for JUNO dated on 2018-01-22: Juno Therapeutics to be Acquired for \$87/Share Cash by Celgene

Financial news for JUNO dated on 2018-01-19: A Survey Of Celgene's M&A Strategy

Financial news for JUNO dated on 2018-01-18: Juno Shares Spike To \$71.21/Shares Up ~3% On The Day

Financial news for JUNO dated on 2018-01-18: Benzinga's Top Upgrades, Downgrades For January 18, 2018

Financial news for JUNO dated on 2018-01-18: Citigroup Downgrades Juno Therapeutics to Neutral

Financial news for JUNO dated on 2018-01-18: 44 Biggest Movers From Yesterday

Financial news for JUNO dated on 2018-01-17: Wall Street Reacts To Celgene's Reported Interest In Juno

Financial news for JUNO dated on 2018-01-17: Mid-Afternoon Market Update: NeuroMetrix Climbs Following Announcement Of Collaboration With GlaxoSmithKline; Aerohive Networks Shares Drop

Financial news for JUNO dated on 2018-01-17: JUNO Option Alert: Feb 16 \$70 Calls at the Ask: 900 @ \$5.8 vs 286 OI; Earnings 2/28 After Close [est] Ref=\$67.8607 Signals 2:17:18pm JUNO JUNO Option Alert: Feb 16 \$70 Calls Above Ask!: 950 @ \$5.81 vs 286 OI; Earnings 2/28 After Close [est] Ref=\$67.84

Financial news for JUNO dated on 2018-01-17: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for JUNO dated on 2018-01-17: Mid-Day Market Update: Dow Surges Over 150 Points; HTG Molecular Diagnostics Shares Plunge

Financial news for JUNO dated on 2018-01-17: bluebird bio Shares Trading Up 10% Following Report Celgene In Talks To Buy Juno; bluebird Likely Being Viewed As A Sympathy Play

Financial news for JUNO dated on 2018-01-17: Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Beats Q4 Expectations

Financial news for JUNO dated on 2018-01-17: Benzinga Pro's 6 Stocks To Watch Today

Financial news for JUNO dated on 2018-01-17: Juno Therapeutics Shares Up 53.6% Premarket Following Report Tues. Afternoon Suggesting Celgene Is In Talks To Purchase Co.

Financial news for JUNO dated on 2018-01-17: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JUNO dated on 2018-01-17: A Peek Into The Markets: U.S. Stock Futures Climb; Goldman Sachs Earnings In Focus

Financial news for JUNO dated on 2018-01-17: 10 Stocks To Watch For January 17, 2018

Financial news for JUNO dated on 2018-01-16: 7 Stocks Moving In Tuesday's After-Hours Session

Financial news for JUNO dated on 2018-01-16: Juno Spokesperson Regarding Dow Jones Report Of Celgene Acquisition Interest Says Co. Doesn't Comment On Market Rumors Or Speculation

Financial news for JUNO dated on 2018-01-16: BZ NOTE: Juno Shares Traded Up ~4.7% On Sept. 14, 2017 Amid Unconfirmed Trader Chatroom Chatter Of Interest From Celgene

Financial news for JUNO dated on 2018-01-16: Juno Shares Up 43.64% After Hours On Dow Jones Report Of Celgene Acquisition Interest

Financial news for JUNO dated on 2018-01-16: Celgene In Talks To Buy Juno Therapeutics

Financial news for JUNO dated on 2018-01-09: JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics

Financial news for JUNO dated on 2018-01-08: How To Trade The JPMorgan Healthcare Conference

Financial news for JUNO dated on 2018-01-05: Needham Initiates Coverage On Juno Therapeutics with Buy Rating, Announces \$65.00 Price Target

Financial news for JUNO dated on 2018-01-02: 4 Reasons To Consider Adding Celldex To Your Portfolio

Financial news for JUNO dated on 2017-12-20: 3 Biotech Pipeline Areas To Keep An Eye On In 2018

Financial news for JUNO dated on 2017-12-20: Juno Therapeutics, Thermo Fisher Scientific Report CAR T Manufacturing Partnership

Financial news for JUNO dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for JUNO dated on 2017-12-12: 42 Biggest Movers From Yesterday

Financial news for JUNO dated on 2017-12-11: 11 Biotech Stocks Moving From ASH 2017

Financial news for JUNO dated on 2017-12-11: 3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise

Financial news for JUNO dated on 2017-12-11: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for JUNO dated on 2017-12-11: UPDATE: Juno Says '74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2'

Financial news for JUNO dated on 2017-12-11: Juno Therapeutics, Celgene Releases Added Data From TRANSCEND Trial Of JCAR017 In Patients With Relapsed, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Financial news for JUNO dated on 2017-12-06: Juno Therapeutics Signs Licensing Agreements with Lilly, OncoTracker, and Fred Hutchinson Cancer Research Center to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition

Financial news for JUNO dated on 2017-12-01: Juno Therapeutics Option Alert: Dec 15 \$50 Calls Sweep (2) at the Ask: 500 @ \$6.3 vs 382 OI; Ref=\$54.635

Financial news for JUNO dated on 2017-11-28: Juno Therapeutics Shares Rebound From Lows But Still Down 6.5% For Session; Traders Recently Circulating Chatter Celgene Has No Interest In Co.; BZ NOTE: Chatter Related To Juno, Celgene Were Heard Several Times Over The Course Of '17

Financial news for JUNO dated on 2017-11-21: Juno Therapeutics Shares Spike To Session Highs, Up 2.2% As Traders Circulate Chatroom Chatter Of Interest From Celgene

Financial news for JUNO dated on 2017-11-06: 9 Notable Biotechs Presenting At This Year's ASH Meeting

Financial news for JUNO dated on 2017-11-03: 4 Biggest Technical Levels To Watch Friday Morning

Financial news for JUNO dated on 2017-11-03: 66 Biggest Movers From Yesterday

Financial news for JUNO dated on 2017-11-02: Juno Therapeutics Shows Promise With Non-Hodgkin Lymphoma Drug

Financial news for JUNO dated on 2017-11-01: Juno Therapeutics Reports Q3 EPS \$(0.73) vs. \$(0.57) In Same Qtr. Last Year, Sales \$44.8M vs. \$20.8M YoY

Financial news for JUNO dated on 2017-11-01: Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH With 15 Abstracts, Notably JCAR017 Data At Dose 2 Level That Showed 80% ORR Rate And 73% CR Rate At 3 Months In

## Core Group

Financial news for JUNO dated on 2017-10-19: Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug

Financial news for JUNO dated on 2017-10-19: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for JUNO dated on 2017-10-18: Trianni Inc. And Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform, Terms Not Disclosed

Financial news for JUNO dated on 2017-10-17: Juno Therapeutics Shares Spike To Session Highs, Now Up 1.9% As Traders Circulate Takeover Chatter Via Chatroom

Financial news for JUNO dated on 2017-09-26: 13D/A Filing From Celgene Switzerland Shows 9.7% Stake In Juno Therapeutics

Financial news for JUNO dated on 2017-09-22: Juno Therapeutics Shares Rebound Strongly Fri. Following Sell Off On News Of \$250M Offering Thurs.; Stock Was Down Nearly 8% Thurs., Now Is Up 11% Fri.

Financial news for JUNO dated on 2017-09-21: Watch These 8 Huge Call Purchases In Thursday Trade

Financial news for JUNO dated on 2017-09-20: Benzinga's Option Alert Recap From September 20

Financial news for JUNO dated on 2017-09-20: Juno Therapeutics Press Release Highlights Launch Of Follow-On Offering Highlighted In Recent SEC Filing: \$225M In Common Stock Plus Option To Buy Up To Added \$33.75M In Shares By Underwriters

Financial news for JUNO dated on 2017-09-20: Filing From Juno Therapeutics Shows Registration For ~\$258.75M Common Stock Offering

Financial news for JUNO dated on 2017-09-20: JUNO Option Alert: Nov 17 \$52.5 Calls Sweep (31) at the Ask: 666 @ \$2.044 vs 107 OI; Ref=\$45.26

Financial news for JUNO dated on 2017-09-15: Wall Street's M&A Chatter From September 14: Juno, Mallinckrodt, Cornerstone OnDemand

Financial news for JUNO dated on 2017-09-14: Celgene Shares Unaffected Following Circulation Of Takeover Interest Related To Juno

Financial news for JUNO dated on 2017-09-14: Juno Therapeutics Shares Up \$0.50 Over Last Min. As Traders Circulate Chatroom Chatter Of Takeover Interest

Financial news for JUNO dated on 2017-09-14: Watch These 6 Huge Put Purchases In Thursday Trade

Financial news for JUNO dated on 2017-09-13: Benzinga's Option Alert Recap From September 13

Financial news for JUNO dated on 2017-09-13: JUNO Option Alert: Oct 20 \$45 Puts Sweep (23) at the Ask: 609 @ \$3.3 vs 272 OI; Ref=\$45.39

Financial news for JUNO dated on 2017-09-12: Morgan Stanley Healthcare Conference Continues Today, Presenters Include: Innoviva, Seattle Genetics, Lab Corp, Anthem, Juno Therapeutics, and Intercept Pharmaceuticals

Financial news for JUNO dated on 2017-09-09: Benzinga's Bulls And Bears For The Past Week: Disney, GE, Tesla And More

Financial news for JUNO dated on 2017-09-07: Breaking Down Barclays' New Bullish Calls On Biotech

Financial news for JUNO dated on 2017-09-07: Benzinga's Top Upgrades, Downgrades For September 7, 2017

Financial news for JUNO dated on 2017-09-07: Citi Biotech Conference Concludes Today, Presenters Include Zymeworks and Juno Therapeutics

Financial news for JUNO dated on 2017-09-07: Barclays Initiates Coverage On Juno Therapeutics with Overweight Rating, Announces \$55.00 Price Target

Financial news for JUNO dated on 2017-09-05: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for JUNO dated on 2017-08-31: Standpoint Research Downgrades Juno Therapeutics to Reduce

Financial news for JUNO dated on 2017-08-30: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JUNO dated on 2017-08-30: Brian Stutland Sees Unusual Options Activity In Juno Therapeutics

Financial news for JUNO dated on 2017-08-30: Watch These 5 Huge Put Purchases In Wednesday Trade

Financial news for JUNO dated on 2017-08-29: Benzinga's Option Alert Recap From August 29

Financial news for JUNO dated on 2017-08-29: Mid-Afternoon Market Update: U.S. Stocks Turn Higher; J.Jill Shares Plummet

Financial news for JUNO dated on 2017-08-29: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for JUNO dated on 2017-08-29: Mid-Day Market Update: Movado Rises After Strong Q2 Results; Finish Line Shares Slide

Financial news for JUNO dated on 2017-08-29: Juno Therapeutics Adds To Monday's Gain After Wedbush Upgrade

Financial news for JUNO dated on 2017-08-29: Juno Therapeutics Option Alert: Oct 20 \$32.5 Puts Sweep (25) at the Bid: 531 @ \$0.71 vs 101 OI; Ref=\$43.2645

Financial news for JUNO dated on 2017-08-29: Benzinga's Top Upgrades, Downgrades For August 29, 2017

Financial news for JUNO dated on 2017-08-29: Raymond James Upgrades Juno Therapeutics to Outperform

Financial news for JUNO dated on 2017-08-29: The Market In 5 Minutes

Financial news for JUNO dated on 2017-08-29: Wedbush Upgrades Juno Therapeutics to Outperform

Financial news for JUNO dated on 2017-08-28: 18 Biggest Mid-Day Gainers For Monday

Financial news for JUNO dated on 2017-08-28: Juno Therapeutics Jumps 17% After Gilead's Purchase Of Kite Pharma

Financial news for JUNO dated on 2017-08-28: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for JUNO dated on 2017-08-18: Lightning Round: Jim Cramer Weighs In On Juno Therapeutics, Halliburton And More

Financial news for JUNO dated on 2017-08-15: Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet

Financial news for JUNO dated on 2017-08-09: Editas Medicine Achieves Milestone Under Collaboration With Juno, Will Receive \$2.5M Payment

Financial news for JUNO dated on 2017-08-07: Facebook, ICICI Bank, Marriott, Juno Therapeutics: Fast Money Picks For August 7

Financial news for JUNO dated on 2017-08-03: Juno Therapeutics Reaffirms Operating Burn \$245M-\$275M

Financial news for JUNO dated on 2017-08-03: Juno Therapeutics Reports Q2 Adj. EPS \$(0.74) vs \$(0.72) Est., Sales \$21.268M vs \$15.82M Est.

Financial news for JUNO dated on 2017-07-20: Juno Therapeutics Spikes Higher On JCAR017 Receiving EU Orphan Designation

Financial news for JUNO dated on 2017-07-13: Juno Shares Down 1.6% After Hours On Chatter Of 7M Share Block Reportedly Being Shopped ~\$27.40/Share

Financial news for JUNO dated on 2017-06-27: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for JUNO dated on 2017-06-13: Goldman Sachs Global Healthcare Conference Begins Today, Presenters Include Mallinckrodt, Jazz Pharma, Community Health, and Juno Therapeutics

Financial news for JUNO dated on 2017-06-08: 15 Biggest Mid-Day Losers For Thursday

Financial news for JUNO dated on 2017-06-08: The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired

Financial news for JUNO dated on 2017-06-08: Benzinga's Top Upgrades, Downgrades For June 8, 2017

Financial news for JUNO dated on 2017-06-08: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for JUNO dated on 2017-06-08: BTIG Research Downgrades Juno Therapeutics to Sell

Financial news for JUNO dated on 2017-06-07: Juno Therapeutics Rated a Strong Buy According to Vetr Members

Financial news for JUNO dated on 2017-06-07: Juno Therapeutics Shares Near Session Lows, Down 4.3%; Hearing Leerink Issues Mid-Day Defense On Name

Financial news for JUNO dated on 2017-06-07: Novartis Exec Says Latest Data For CTL019 Similar To Results From Rivals' Blood Cancer Trials, Showed Overall Response Rate At 3 Months In Adults Was 45%, 37% Complete Responses

Financial news for JUNO dated on 2017-06-06: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for JUNO dated on 2017-06-06: Juno Therapeutics, Priceline, Square: Fast Money Picks For June 6

Financial news for JUNO dated on 2017-06-05: 12 Biggest Mid-Day Losers For Monday

Financial news for JUNO dated on 2017-06-05: Mid-Day Market Update: Crude Oil Down 1%; Forestar Shares Spike Higher

Financial news for JUNO dated on 2017-06-05: Mid-Morning Market Update: Markets Mostly Flat; Herbalife Expects Lower Q2 Sales

Financial news for JUNO dated on 2017-05-26: Watch These 7 Huge Put Purchases In Friday Trade

Financial news for JUNO dated on 2017-05-25: Benzinga's Option Alert Recap From May 25

Financial news for JUNO dated on 2017-05-25: Option Alert: JUNO Jun 25.0 Puts Sweep: 530 @ ASK \$1.42: 2062 traded vs 80 OI: Earnings 8/3 After Close (est) \$25.51 Ref

Financial news for JUNO dated on 2017-05-25: Option Alert: JUNO Jul 30.0 Calls Sweep: 744 @ ASK \$1.00: 1301 traded vs 166 OI: Earnings 8/3 After Close (est) \$25.69 Ref

Financial news for JUNO dated on 2017-05-22: Vetr Upgrades Juno To Buy Amid Volatile May

Financial news for JUNO dated on 2017-05-16: Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics

Financial news for JUNO dated on 2017-05-08: Vetr Urges Buy On Juno After Earnings

Financial news for JUNO dated on 2017-05-08: Analyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity

Financial news for JUNO dated on 2017-05-04: Juno Therapeutics Reports Q1 Adj. EPS \$(0.71) In-line With Est., Sales \$19.327M vs \$13.47M Est.

Financial news for JUNO dated on 2017-04-26: Freeport-McMoRan, Juno Therapeutics, Square And European Banks: Fast Money Picks For April 26

Financial news for JUNO dated on 2017-04-10: 6 Stocks To Watch For April 10, 2017

Financial news for JUNO dated on 2017-03-16: Barclays Global Healthcare Conference Concludes Today; Presenters Include DexCom, NantKwest, Juno, Humana, And Ironwood Pharma

Financial news for JUNO dated on 2017-03-07: Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio

Financial news for JUNO dated on 2017-03-02: Vetr Crowd In Lockstep With Market In

Opting To Sell Juno

Financial news for JUNO dated on 2017-03-02: 20 Biggest Mid-Day Losers For Thursday

Financial news for JUNO dated on 2017-03-02: Wedbush Asks: How Does Kite Pharma's ZUMA-1 Compare To Juno's TRANSCEND?

Financial news for JUNO dated on 2017-03-02: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for JUNO dated on 2017-03-01: Juno Therapeutics Reports Q4 EPS \$(0.51) vs \$(0.61) Est., Sales \$21.153M vs \$14.56M Est.

Financial news for JUNO dated on 2017-03-01: Costco, Juno, Monsanto, Target: Fast Money Picks For March 1

Financial news for JUNO dated on 2017-02-23: Benzinga's Top Upgrades, Downgrades For February 23, 2017

Financial news for JUNO dated on 2017-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2017

Financial news for JUNO dated on 2017-02-22: Wells Fargo Initiates Coverage On Juno Therapeutics At Outperform

Financial news for JUNO dated on 2017-02-13: Key Presenters At Leerink's Healthcare Conference

Financial news for JUNO dated on 2017-02-01: Wedbush Initiates Coverage On Juno Therapeutics at Neutral, Announces \$24.00 Target

Financial news for JUNO dated on 2017-01-18: Option Alert: Juno Therapeutics Feb 25.0 Calls Sweep: 1016 @ ASK \$0.499: 1032 traded vs 392 OI: Earnings 2/28 After Close (est) \$20.32 Ref

Financial news for JUNO dated on 2017-01-18: Recent Strength In Juno Therapeutics Being Attributed To M&A Chatter

Financial news for JUNO dated on 2017-01-09: TheStreet's Adam Feuerstein Tweets '\$CELG spending a lot of time talking up pipeline from partners. \$BLUE \$XLRN etc. #JPM17'

Financial news for JUNO dated on 2016-12-30: Option Alert: JUNO Jan 22.5 Calls Sweep: 604 @ ASK \$0.40: 604 traded vs 2667 OI: Earnings 2/28 After Close (est) \$19.16 Ref

Financial news for JUNO dated on 2016-12-20: Juno Therapeutics' and Celgene Corporation's Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA

Financial news for JUNO dated on 2016-12-19: Juno Therapeutics Defeats Kite Pharma's Challenge to CAR T-Cell Patent

Financial news for JUNO dated on 2016-12-13: Stocks Hitting 52-Week Lows

Financial news for JUNO dated on 2016-12-09: 10 Stocks With Lowest Close In Three Weeks

Financial news for JUNO dated on 2016-12-08: Stocks Hitting 52-Week Lows

Financial news for JUNO dated on 2016-12-07: 10 Stocks With Lowest Close In Three Weeks

Financial news for JUNO dated on 2016-12-06: UPDATE: Juno Notes 88% CD19-Negative Patients Achieved CR At Level 2 Dose, 93% Showed CR In JCAR017 In Pediatric ALL Patients

Financial news for JUNO dated on 2016-12-06: UPDATE: TRANSCEND Study Of JCAR017 In NHL Shows 80% ORR, 60% Complete Response Rate Along With No Severe Cytokine Release And 14% Rate Of Severe Neurotoxicity

Financial news for JUNO dated on 2016-12-06: Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH

Financial news for JUNO dated on 2016-12-06: 18 Biggest Mid-Day Losers For Tuesday

Financial news for JUNO dated on 2016-12-06: Stocks Hitting 52-Week Lows

Financial news for JUNO dated on 2016-12-06: Benzinga's Top Downgrades

Financial news for JUNO dated on 2016-12-06: The Market In 5 Minutes: Lower Oil Prices, Higher Apple Watch Sales

Financial news for JUNO dated on 2016-12-06: Raymond James Downgrades Juno Therapeutics to Market Perform

Financial news for JUNO dated on 2016-12-05: American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena

Financial news for JUNO dated on 2016-12-05: Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response, 80% Overall Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma

Financial news for JUNO dated on 2016-12-05: CNBC's Meg Tirrell Tweets: #ASH16 stocks looking largely opposite of last year. So far: \$KITE +9.4% \$JUNO +6.6% \$ONCE +2.5% On flip side: \$GBT -3.3% \$AGIO -12%

Financial news for JUNO dated on 2016-12-03: Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL at ASH 2016

Financial news for JUNO dated on 2016-12-01: Bluebird News A Positive For Juno, Kite Pharma

Financial news for JUNO dated on 2016-11-29: 10 Stocks With Lowest Close In Three Weeks

Financial news for JUNO dated on 2016-11-28: 7 Biggest Price Target Changes For Monday

Financial news for JUNO dated on 2016-11-25: 5 Biggest Price Target Changes For Friday

Financial news for JUNO dated on 2016-11-25: The Market In 5 Minutes: Black Friday Closes Shortened Trading Week

Financial news for JUNO dated on 2016-11-25: Benzinga's Top Downgrades

Financial news for JUNO dated on 2016-11-25: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for JUNO dated on 2016-11-25: SunTrust Robinson Humphrey Downgraded Juno Therapeutics to Hold Late Wednesday, Lowered Target to \$25.00

Financial news for JUNO dated on 2016-11-25: 10 Stocks With Lowest Close In Three Weeks

Financial news for JUNO dated on 2016-11-23: Mid-Afternoon Market Update: Caleres Rises On Earnings Beat; Juno Therapeutics Shares Slide

Financial news for JUNO dated on 2016-11-23: Juno Therapeutics' Hold Is 'More Impactful To Sentiment Than Estimates'

Financial news for JUNO dated on 2016-11-23: A Tough Day For Some Biotech Bulls

Financial news for JUNO dated on 2016-11-23: 18 Biggest Mid-Day Losers For Wednesday

Financial news for JUNO dated on 2016-11-23: Mid-Day Market Update: Eli Lilly Tumbles After Alzheimer's Study Fails To Meet Goals; Euroseas Shares Rise

Financial news for JUNO dated on 2016-11-23: Stocks Hitting 52-Week Lows

Financial news for JUNO dated on 2016-11-23: Mid-Morning Market Update: Markets Mostly Lower; Deere Tops Q4 Views

Financial news for JUNO dated on 2016-11-23: Juno Therapeutics Plummets 30% After Leukemia Drug Is Placed On Hold

Financial news for JUNO dated on 2016-11-23: Adam Feuerstein @adamfeuerstein 28s Seems highly likely, necessary, for FDA to shut down \$JUNO entirely, all CAR-T programs, until they figure out what is going wrong.

Financial news for JUNO dated on 2016-11-23: Juno Says Deaths Unrelated To Manufacturing Process on Conf. Call

Financial news for JUNO dated on 2016-11-23: Juno Executives Say They Aren't Sure Whether To Discontinue Trial, Still Looking At Data



Financial news for JUNO dated on 2016-11-23: Juno Shares Resume Trade, Down 43% At \$16.75 Premarket

Financial news for JUNO dated on 2016-11-23: Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold After 2 Patients Suffer Cerebral Edema Earlier This Week, One Patient Has Died and Other Patient Not Expected To Recover

Financial news for JUNO dated on 2016-11-09: Juno Reaffirms FY16 Outlook

Financial news for JUNO dated on 2016-11-09: Juno Therapeutics Reports Q3 Adj. EPS \$(0.57) vs \$(0.55) Est., Sales \$20.8M vs \$10.6M Est.

Financial news for JUNO dated on 2016-11-09: Earnings Scheduled For November 9, 2016

Financial news for JUNO dated on 2016-11-04: BTIG Is No Longer Selling Juno Therapeutics Stock

Financial news for JUNO dated on 2016-11-04: Benzinga's Top Upgrades

Financial news for JUNO dated on 2016-11-04: The Market In 5 Minutes: Jobs Numbers, Big Earnings Close The Week

Financial news for JUNO dated on 2016-11-04: BTIG Research Upgrades Juno Therapeutics, Inc. - Common Stock to Neutral

Financial news for JUNO dated on 2016-10-31: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for JUNO dated on 2016-10-24: Watch These 5 Huge Call Purchases In Monday Trade

Financial news for JUNO dated on 2016-10-21: Option Alert: JUNO Dec16 30.0 Calls: 2000 @ ASK \$2.05: 2000 traded vs 137 OI: Earnings 11/8 After Market (unconf) \$27.69 Ref

Financial news for JUNO dated on 2016-09-27: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for JUNO dated on 2016-09-27: Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19

Financial news for JUNO dated on 2016-09-27: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for JUNO dated on 2016-09-26: Juno Up 10% After Hours In Sympathy To Kite Pharma Top-Line Results

Financial news for JUNO dated on 2016-09-08: 15 Biggest Mid-Day Gainers For Thursday

Financial news for JUNO dated on 2016-09-08: BTIG Negative On Juno Therapeutics, Says Paper Reviewing CD8+ And CD4+ 'does not alter our Sell rating'

Financial news for JUNO dated on 2016-09-08: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for JUNO dated on 2016-08-31: Sell Juno Therapeutics: BTIG Says It's Trailing The Competition

Financial news for JUNO dated on 2016-08-31: BTIG Is 'Generally Skeptical' On Kite Pharma Expectations

Financial news for JUNO dated on 2016-08-30: BTIG Research Initiates Coverage on Juno Therapeutics at Sell, Announces \$23.00 PT

Financial news for JUNO dated on 2016-08-22: Juno Therapeutics Rebound Will Continue, Vetr Crowd Says

Financial news for JUNO dated on 2016-08-18: 11 Biopharma CEOs To Follow On Twitter

Financial news for JUNO dated on 2016-08-04: Juno Therapeutics Reports Q2 EPS \$(0.64) vs. Est. \$(0.41), Rev. \$27.6M vs. Est. \$14.26M

Financial news for JUNO dated on 2016-07-28: Short-Sellers Favor These 2 Biotech Stocks In July

Financial news for JUNO dated on 2016-07-15: 12 Stocks Moving In Friday's Pre-Market Session

Financial news for JUNO dated on 2016-07-14: Juno Therapeutics Reports Purchase of

RedoxTherapies for Upfront Payment of \$10M in Cash Plus Clinical, Commercial Milestones

Financial news for JUNO dated on 2016-07-13: Mid-Afternoon Market Update: Juno Therapeutics Rises After JCAR015 Phase 2 Rocket Trial Resumption; Avinger Shares Tumble

Financial news for JUNO dated on 2016-07-13: 8 Biggest Mid-Day Gainers For Wednesday

Financial news for JUNO dated on 2016-07-13: Mid-Day Market Update: Crude Oil Down Over 4%; Imprivata Shares Surge Following Deal with Thoma Bravo

Financial news for JUNO dated on 2016-07-13: Benzinga's Volume Movers

Financial news for JUNO dated on 2016-07-13: Juno Therapeutics Shares Edging Lower Following Co. Press Release Disclosing CEO Sued for Securities Fraud

Financial news for JUNO dated on 2016-07-13: Mid-Morning Market Update: Markets Mostly Flat; Commerce Bancshares Profit Beats Views

Financial news for JUNO dated on 2016-07-13: Juno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption

Financial news for JUNO dated on 2016-07-13: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JUNO dated on 2016-07-13: Juno Therapeutics +27.7% Premarket @\$35.50; Co Announced Tuesday it Would Resume JCAR015 Phase 2 Rocket Trial

Financial news for JUNO dated on 2016-07-12: Juno Shares Up ~19% After-Hours Following News Of Drug Trial Resuming

Financial news for JUNO dated on 2016-07-12: Juno Therapeutics To Resume JCAR015 Phase 2 Rocket Trial

Financial news for JUNO dated on 2016-07-11: Must Watch Stocks for July 11, 2016

Financial news for JUNO dated on 2016-07-08: Mid-Afternoon Market Update: Dow Surges 250 Points; Juno Therapeutics Shares Tumble

Financial news for JUNO dated on 2016-07-08: Barclays Morning Research Summary: Commodities, Comcast And Healthcare In Focus

Financial news for JUNO dated on 2016-07-08: 8 Biggest Mid-Day Losers For Friday

Financial news for JUNO dated on 2016-07-08: Mid-Day Market Update: PriceSmart Drops Following Weak Q3 Results; Eleven Biotherapeutics Shares Spike Higher

Financial news for JUNO dated on 2016-07-08: These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold

Financial news for JUNO dated on 2016-07-08: Mid-Morning Market Update: Markets Open Higher; Siris Capital Group To Buy Polycom For \$2 Billion

Financial news for JUNO dated on 2016-07-08: 7 Largest Price Target Changes For Friday

Financial news for JUNO dated on 2016-07-08: Juno Therapeutics Spikes to Premarket High of \$32.30

Financial news for JUNO dated on 2016-07-08: Benzinga's Top Downgrades

Financial news for JUNO dated on 2016-07-08: The Market In 5 Minutes: Huge Beat For June's U.S. Jobs Numbers

Financial news for JUNO dated on 2016-07-08: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for JUNO dated on 2016-07-08: Juno Therapeutics Price Target Cut From \$63 To \$39 At JPMorgan

Financial news for JUNO dated on 2016-07-08: JP Morgan Downgrades Juno Therapeutics to Neutral, Lowers PT to \$39.00

Financial news for JUNO dated on 2016-07-07: Juno Says 2017 Approval For JCAR015 Off Table On Conf. Call

Financial news for JUNO dated on 2016-07-07: Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer Drug

Financial news for JUNO dated on 2016-07-07: Juno Shares Fall To Low Of \$27.76, Now At \$30/Share Down 30% After Hours

Financial news for JUNO dated on 2016-07-07: CORRECTION: Juno Therapeutics Shares to Resume Trade at 4:35 p.m. EDT

Financial news for JUNO dated on 2016-07-07: Juno Therapeutics Shares to Resume Trade at 4:35 p.m. EDT

Financial news for JUNO dated on 2016-07-07: BlueBid Bio Sells Off to Low of \$45.08 on Juno Clinical Hold News

Financial news for JUNO dated on 2016-07-07: UPDATE: Juno Therapeutics Clinical Hold Initiated After 2 Patient Deaths Last Week Followed By Recent Addition Of Fludarabine To Pre-Conditioning Regimen

Financial news for JUNO dated on 2016-07-07: Juno Reports Clinical Hold on JCAR015 Phase 2 Trial

Financial news for JUNO dated on 2016-07-07: Juno Pharma Shares Halted News Pending

Financial news for JUNO dated on 2016-07-06: Benzinga's Top Initiations

Financial news for JUNO dated on 2016-07-06: The Market In 5 Minutes: Gold Hits Highest Level Since 2014

Financial news for JUNO dated on 2016-07-06: Barclays Initiates 2 Cellular Cancer Therapy Plays With Equal-Weight Rating

Financial news for JUNO dated on 2016-07-06: Barclays Initiates Coverage on Juno Therapeutics at Equal-weight, Announces \$48.00 PT

Financial news for JUNO dated on 2016-06-15: Option Alert: JUNO Aug16 40.0 Calls: 1000 @ ASK \$5.70: 1000 traded vs 325 OI: \$42.34 Ref

Financial news for JUNO dated on 2016-06-15: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for JUNO dated on 2016-06-14: 4 Stocks Moving In Tuesday's After-Hours Session: Earnings, Corrections, Asset Sales

Financial news for JUNO dated on 2016-06-14: Juno Spikes to \$43.85 on Vol

Financial news for JUNO dated on 2016-06-09: Juno Therapeutics Could Now Return 18.6%, Vetr Crowd Says

Financial news for JUNO dated on 2016-06-06: Monday's Top 7 Pre-Market Gainers

Financial news for JUNO dated on 2016-06-06: Juno Therapeutics Bid Up 4.7% @\$48 Following Announcement of Encouraging Clinical Data from CAR T Cell Product Candidates

Financial news for JUNO dated on 2016-06-04: Juno Therapeutics Announced Encouraging Clinical Data from CAR T Cell Product Candidate JCAR015, at #ASCO16

Financial news for JUNO dated on 2016-06-04: Juno Therapeutics Announced that its Investigational Chimeric Antigen Receptor (CAR) T Cell Product Candidates are Demonstrating Encouraging Clinical Outcomes for Adults, Children with B-cell Malignancies; Data to be Presented at #ASCO16

Financial news for JUNO dated on 2016-06-02: Raymond James Initiates Coverage on Juno Therapeutics at Outperform

Financial news for JUNO dated on 2016-05-25: Seattle Children's, Juno Therapeutics Accelerate T-Cell Immunotherapy Clinical Trials for Children, Adults With Deadly Brain Cancers

Financial news for JUNO dated on 2016-05-09: Juno Therapeutics Q1 EPS (\$0.78) vs (\$0.52) est, Revenue \$9.78M vs \$4.65M est

Financial news for JUNO dated on 2016-05-06: The Market In 5 Minutes: The Most Exciting Two Minutes In Sports

Financial news for JUNO dated on 2016-05-06: Benzinga's Top Initiations

Financial news for JUNO dated on 2016-05-05: Cowen & Company Initiates Coverage on Juno Therapeutics at Outperform

Financial news for JUNO dated on 2016-04-26: StreetSweeper Short Bio-Path: 'Unfortunate' Analyst Support, Little Executive Biotech Experience

Financial news for JUNO dated on 2016-04-25: The Market In 5 Minutes: Monday, April 25, 2016

Financial news for JUNO dated on 2016-04-24: Benzinga's Weekend M&A Chatter

Financial news for JUNO dated on 2016-04-22: Bellicum Pharma Shares Moving Higher; Traders Attributing to Chatter of Potential Bid from Juno

Financial news for JUNO dated on 2016-04-20: Juno's Investigational CAR T Cell Product Candidates JCAR018 and JTCR016 Demonstrate Encouraging Clinical Responses in Patients with B-Cell and Mesothelioma Cancers

Financial news for JUNO dated on 2016-04-20: 2 Winners From AACR Flying Under The Radar

Financial news for JUNO dated on 2016-04-11: Celgene, Juno Therapeutics Announce Celgene Exercised Option to Develop, Commercialize CD19-Directed Product Candidates; Juno to Receive \$50M Opt-In Payment

Financial news for JUNO dated on 2016-04-07: Juno Therapeutics, WuXi AppTec Report New Company to Develop Novel Cell-Based Cancer Immunotherapies in China

Financial news for JUNO dated on 2016-04-07: Baillie Gifford Reports 10.49% Passive Stake in Juno Therapeutics in 13G

Financial news for JUNO dated on 2016-03-17: Kite, Juno 'Well Positioned' To Win From AACR

Financial news for JUNO dated on 2016-03-11: Vetr's Top Raters Bullish On Juno Therapeutics

Financial news for JUNO dated on 2016-03-09: Jim Cramer Advises Viewers On AstraZeneca, Juno Therapeutics, Enbridge Energy Partners, Lockheed Martin And Microsoft

Financial news for JUNO dated on 2016-03-07: The 5 Most Notable Insider Sells Of The Week

Financial news for JUNO dated on 2016-02-26: Juno Therapeutics Rally Aided By Vetr Rating

Financial news for JUNO dated on 2016-02-26: Juno Therapeutics Upgraded By Vetr Top Raters, 100% Of Crowd Bullish

Financial news for JUNO dated on 2016-02-25: Citigroup Initiates Coverage on Juno Therapeutics at Buy

Financial news for JUNO dated on 2016-02-23: Juno Therapeutics, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center Announce New Immuno-oncology Clinical Trials Uni

Financial news for JUNO dated on 2016-02-23: Vetr Top Raters Upgrade Juno Therapeutics To 4.5-Star Stock

Financial news for JUNO dated on 2016-02-17: Benzinga's Top Upgrades

Financial news for JUNO dated on 2016-02-17: Guggenheim Securities Upgrades Juno Therapeutics to Buy

Financial news for JUNO dated on 2016-02-02: Option Alert: JUNO Jan17 55.0 Calls: 1762 @ ASK \$1.40: 2510 traded vs 95 OI: Earnings 3/16 \$24.62 Ref

Financial news for JUNO dated on 2016-01-29: SunTrust Robinson Humphrey Initiates Coverage on Juno Therapeutics at Buy, Announces \$50.00 PT

Financial news for JUNO dated on 2016-01-22: Option Alert: JUNO May16 37.5 Calls Sweep: 839 @ ASK \$3.30: 839 traded vs 113 OI: Earnings 3/16 \$33.12 Ref

Financial news for JUNO dated on 2016-01-11: Juno Therapeutics Lower, To Acquire AbVitro For \$78 Million In Cash And Nearly 1.30 Million Shares

Financial news for JUNO dated on 2016-01-11: This Week Is Paramount For Biotech Stocks

Financial news for JUNO dated on 2016-01-11: Juno Therapeutics Acquires AbVitro For \$78M Cash And 1.289M Shares Of JUnO Stock, To License AbVitro Technology Rights AND

Grant Certain Product Option Rights To Celgene

Financial news for JUNO dated on 2016-01-07: Napodano: Here Is Actinium's Place Among The CAR-T Hype & Radiopharma Busts

Financial news for JUNO dated on 2016-01-07: Eureka Therapeutics, Juno Therapeutics Report Exclusive License Agreement For Use Of A Novel Fully-Human MUC16 Binder In Car T Cell Immunotherapy

Financial news for JUNO dated on 2016-01-05: Editas Medicine, Backed By Google And Bill Gates, Files \$100 Million IPO

Financial news for JUNO dated on 2015-12-15: Standpoint Research Upgrades Juno Therapeutics to Buy

Financial news for JUNO dated on 2015-12-13: More Wild Short Interest Swings In Biotech Stocks

Financial news for JUNO dated on 2015-12-08: Vetr Crowd Sees Juno Therapeutics As A Five-Star Stock

Financial news for JUNO dated on 2015-12-06: Juno's JCAR014, JCAR018 Demonstrate Encouraging Clinical Responses in Patients with B-Cell Cancers at #ASH2015

Financial news for JUNO dated on 2015-11-30: Leerink Highlights Biotechs Poised To Benefit From ASH Conference

Financial news for JUNO dated on 2015-11-18: Goldman Sachs Initiates Coverage on Juno Therapeutics at Neutral, Announces \$50.00 PT

Financial news for JUNO dated on 2015-11-14: Ronnie Moas Downgrades Kite Pharma, Sees \$100 Stock Price Through 2018

Financial news for JUNO dated on 2015-11-10: Juno Therapeutics shares up ~1.5% following earnings

Financial news for JUNO dated on 2015-11-10: Juno Therapeutics Reports Q3 EPS (\$0.26) Vs Est (\$0.41)

Financial news for JUNO dated on 2015-11-05: Andy Biotech Tweets: #ASH15 Abstracts. Tweet Has Links To Each Biotech Company's Abstract

Financial news for JUNO dated on 2015-10-29: Standpoint Research Downgrades Juno Therapeutics to Hold

Financial news for JUNO dated on 2015-10-19: Here's Why Biotechs Fell On Monday

Financial news for JUNO dated on 2015-10-15: Dyax, Juno Therapeutics Soar Following Biotech Index Rebalance

Financial news for JUNO dated on 2015-10-15: CORRECTION: NYSE Arca Biotech Index Fund Announced That It Did Rebalance

Financial news for JUNO dated on 2015-10-15: NYSE Arca Biotech Index Fund Announced At 11:45 EDT That It Would Be Rebalancing, Will Add DYAX And JUNO and Remove EXAS and PDLI

Financial news for JUNO dated on 2015-10-15: UPDATE: Broker at First Trust NYSE Arca Biotech Index Fund Said Fund Never Announces Additions on a Friday, and Never Announce Ahead of Time Which Changes Will Be Made

Financial news for JUNO dated on 2015-10-15: Broker at First Trust NYSE Arca Biotech Index Fund Can Not Confirm Addition of Dyax, Juno Therapeutics, Says Also Heard Similar Rumor

Financial news for JUNO dated on 2015-10-15: Hearing Dyax Inc And Juno Therapeutics Being Added To First Trust NYSE ARca Biotechnology Index Fund; PDL Biopharama And Exact Sciences To be Removed, Effective At The Close On Friday Oct 16

Financial news for JUNO dated on 2015-10-15: Juno Spikes to High on Volume

Financial news for JUNO dated on 2015-10-12: Wild Short Interest Swings For These Three Biotech Stocks

Financial news for JUNO dated on 2015-10-08: Short Selling: Karl Loomes Picks The Six Hottest U.S.-Listed Stocks

Financial news for JUNO dated on 2015-10-06: Strength in Juno Therapeutics Being Attributed by Some Traders to Article on CMLVIZ.com

Financial news for JUNO dated on 2015-10-06: Juno Therapeutics Spikes to High

Financial news for JUNO dated on 2015-10-06: FBR Met With Juno's Management; Here's What Happened

Financial news for JUNO dated on 2015-10-01: Juno Therapeutics Presenting Now at Leerink Immuno-Oncology Roundtable

Financial news for JUNO dated on 2015-09-14: Amgen And Biogen Lead Short Interest Surge In Biotechs

Financial news for JUNO dated on 2015-08-25: Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health

Financial news for JUNO dated on 2015-08-25: What Should Biotech Investors Do Now?

Financial news for JUNO dated on 2015-08-24: 6 Stocks Ronnie Moas Is Shopping For Amid Market Selloff

Financial news for JUNO dated on 2015-08-24: Standpiont's Ronnie Moas Says Hes 'Going Shopping' as DJIA Opens Down 800 Points: Upgrades Qualcomm, Wesco to Buy, Initiates Alibaba, Macy's, United Air, Juno Therapeutics with Buys

Financial news for JUNO dated on 2015-08-24: Standpoint Research Initiates Coverage on Juno Therapeutics at Buy, Announces \$47.00 PT

Financial news for JUNO dated on 2015-08-22: Costa: 7 Stocks Market Technicians Should Keep An Eye On

Financial news for JUNO dated on 2015-08-18: Juno Therapeutics Could Nearly Double On Data, Multiple Catalysts, Say FBR Analysts

Financial news for JUNO dated on 2015-08-18: FBR Capital Initiates Coverage on Juno Therapeutics at Outperform, Announces \$73.00 PT

Financial news for JUNO dated on 2015-08-12: Juno Therapeutics Reports Q2 Loss \$0.35 Vs Est Loss \$0.31

Financial news for JUNO dated on 2015-07-30: Juno Announces FDA Clearance of Investigational NDA for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

Financial news for JUNO dated on 2015-07-23: Celgene's Q2 Earnings Call: Highlights & Analyst Commentary

Financial news for JUNO dated on 2015-07-22: Benzinga's Top Initiations

Financial news for JUNO dated on 2015-07-22: Northland Securities Initiates Coverage on Juno Therapeutics at Outperform, Announces \$64.00 PT

Financial news for JUNO dated on 2015-07-20: BofA Starts Collectis At Buy, Sees Plant Sciences As 'Hidden Gem'

Financial news for JUNO dated on 2015-07-08: SEC Filing: Celgene Reports 9.1% Stake In Juno Therapeutics

Financial news for JUNO dated on 2015-07-02: Benzinga's Top #PreMarket Losers

Financial news for JUNO dated on 2015-07-01: JPMorgan Comments On Juno Therapeutics, Celgene

Financial news for JUNO dated on 2015-07-01: UPDATE: Traders Attributing Spike Higher in Juno Shares to Positive Comment from Co. Pres, CEO Hans Edgar Bishop on CNBC

Financial news for JUNO dated on 2015-07-01: Juno Therapeutics Shares Spike Higher

Financial news for JUNO dated on 2015-07-01: CNBC's Stock Pops & Drops From June 30

Financial news for JUNO dated on 2015-06-30: Is Celgene Risking Too Much For Too Little By Partnering With Juno Therapeutics?

Financial news for JUNO dated on 2015-06-30: Morgan Stanley Just Cut Juno Therapeutics' Price Target

Financial news for JUNO dated on 2015-06-30: Morgan Stanley Maintains Equal-weight on Juno Therapeutics, Lowers PT to \$54.00

Financial news for JUNO dated on 2015-06-30: Mid-Day Market Update: Juno Therapeutics

Jumps Following Announcement of 10-Year Collaboration With Celgene

Financial news for JUNO dated on 2015-06-30: Juno Therapeutics CEO Weighs In On Celgene Partnership, T-Cell Innovations

Financial news for JUNO dated on 2015-06-30: Tuesday's Mid-Day Movers: Juno, Fitbit, Kandi Spike; Puerto Rico News Affecting Stocks

Financial news for JUNO dated on 2015-06-30: Analysts Diverge On Celgene's Deal With Juno Therapeutics

Financial news for JUNO dated on 2015-06-30: Benzinga's Volume Movers

Financial news for JUNO dated on 2015-06-30: Cantor Reiterates Buy On Celgene As It Loads Up On CAR-T

Financial news for JUNO dated on 2015-06-30: Mid-Morning Market Update: Markets Rise; ConAgra Foods Plans To Exit Private Label Business

Financial news for JUNO dated on 2015-06-30: Morning Market Gainers

Financial news for JUNO dated on 2015-06-30: Benzinga's Top #PreMarket Losers

Financial news for JUNO dated on 2015-06-30: Morgan Stanley: Celgene-Juno Partnership Good For One Side, But Neutral For The Other

Financial news for JUNO dated on 2015-06-30: Benzinga's Top #PreMarket Gainers

Financial news for JUNO dated on 2015-06-30: US Stock Futures Gain Ahead Of Economic Data

Financial news for JUNO dated on 2015-06-30: Juno Therapeutics Signs \$1 Billion Development Pact With Celgene

Financial news for JUNO dated on 2015-06-30: JUNO CEO Hans Bishop On CNBC Says 'deal is transformative for us'

Financial news for JUNO dated on 2015-06-30: Stocks To Watch For June 30, 2015

Financial news for JUNO dated on 2015-06-29: Juno Therapeutics, Kite Pharma, Eleven Bio Lead Monday's After-Hours Movers

Financial news for JUNO dated on 2015-06-29: Juno Shares Rise 64% After-Hours Following Announcement of Ten-Year Collaboration With Celgene

Financial news for JUNO dated on 2015-06-29: Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases

Financial news for JUNO dated on 2015-06-29: Juno Reports FDA Acceptance of Investigational New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

Financial news for JUNO dated on 2015-06-18: Morning Market Gainers

Financial news for JUNO dated on 2015-06-18: Benzinga's Top Initiations

Financial news for JUNO dated on 2015-06-18: Maxim Group Initiates Juno Therapeutics With Buy

Financial news for JUNO dated on 2015-06-18: Benzinga's Top #PreMarket Gainers

Financial news for JUNO dated on 2015-06-18: Maxim Group Initiates Coverage on Juno Therapeutics at Buy

Financial news for JUNO dated on 2015-06-12: Cancer Drug Conference Gives Sector A Boost

Financial news for JUNO dated on 2015-06-02: Benzinga's M&A Chatter for Wednesday June 2, 2015

Financial news for JUNO dated on 2015-06-02: Juno Shares Falling; May be Attributed to Bloomberg Correcting Earlier Story of AstraZeneca CEO Saying Would Buy Co Such as Juno

Financial news for JUNO dated on 2015-06-02: Report: AstraZeneca Might Bid On Juno Therapeutics

Financial news for JUNO dated on 2015-06-02: AstraZeneca CEO Soriot Said CAR T

Therapy Candidates Would Need to Be Able to Manage Side Effects Before Co. Would Be Interested in Deal

Financial news for JUNO dated on 2015-06-02: Shares of Juno Therapeutics Resume, Now Trading Up Nearly 12%

Financial news for JUNO dated on 2015-06-02: Hearing AstraZeneca CEO Pascal Soriot Has Suggested Co. 'Would Consider' Cos. Like Juno, Will Partner for Further Immunotherapy Trials

Financial news for JUNO dated on 2015-06-02: UPDATE: Juno Therapeutics Shares Halted Up ~11.6%

Financial news for JUNO dated on 2015-06-02: Shares of Juno Halted on Circuit Breaker

Financial news for JUNO dated on 2015-06-02: Shares of Ziopharm, Juno Moving Higher; Note Being Circulated Says Juno, Ziopharm Potential Targets of AstraZeneca

Financial news for JUNO dated on 2015-06-02: Morning Market Gainers

Financial news for JUNO dated on 2015-06-02: Juno Therapeutics Shares Rise 2.5% Premarket Following Announcement of Acquisition of X-Body

Financial news for JUNO dated on 2015-06-02: Juno Therapeutics Announces Purchase of X-BODY for ~\$21M in Cash, ~439K Shares of JUNO Initially

Financial news for JUNO dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for JUNO dated on 2015-06-01: Juno Therapeutics Reports JCAR014 Showed 'Encouraging' Clinical Responses, Translational Insights in Patients with B-Cell Cancers

Financial news for JUNO dated on 2015-05-30: Juno's Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses in Patients With B-Cell Cancers

Financial news for JUNO dated on 2015-05-28: Juno THERapeutics Names Hyam Levitsky Chief Scientific Officer

Financial news for JUNO dated on 2015-05-27: Juno Therapeutics Reports Exclusive Collaboration Deal with Editas Medicine for Creation of Next-Gen CAR T, TCR Cell Therapies

Financial news for JUNO dated on 2015-05-13: 3 Biotech Stocks See Growing Short Interest

Financial news for JUNO dated on 2015-05-11: Juno Therapeutics Reports Q1 EPS \$(0.30) vs. Est. \$(0.34)

Financial news for JUNO dated on 2015-05-11: Juno Therapeutics Acquires Stage Cell Therapeutics

Financial news for JUNO dated on 2015-05-11: Fast Money Picks For May 11

Financial news for JUNO dated on 2015-05-06: Investing In Personalized Cancer Treatment

Financial news for JUNO dated on 2015-05-06: Morning Market Gainers

Financial news for JUNO dated on 2015-05-06: Fate Therapeutics Shares Rise 83% Premarket Following Announcement of Deal with Juno

Financial news for JUNO dated on 2015-05-06: UPDATE: Juno Will Buy ~1M Shares of Fate Therapeutics at \$8/Share, Co. Will Make Upfront \$5M Payment to Fate, Eligible for Up to \$50M in Selection Fees

Financial news for JUNO dated on 2015-05-06: Juno Therapeutics, Fate Therapeutics Partner For Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies

Financial news for JUNO dated on 2015-05-06: Juno Therapeutics, Fate Therapeutics Report Strategic Research Deal

Financial news for JUNO dated on 2015-04-28: 3 Biotech Stocks With Rising Short Interest

Financial news for JUNO dated on 2015-04-27: Gene Therapy Stocks Take Beating On Bad News For Celladon



Financial news for JUNO dated on 2015-04-21: Adam Feuerstein @adamfeuerstein Tweet: \$JUNO spox confirms today's '017 data new (more patients, longer follow up.) At ASH14, CR rate was 85% (11/13)

Financial news for JUNO dated on 2015-04-21: Shares of Juno Therapeutics Resume Trade; Now Up to \$58.25

Financial news for JUNO dated on 2015-04-21: Shares of Juno Therapeutics Halted on Circuit Breaker, Now Up 4+%

Financial news for JUNO dated on 2015-04-21: Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) Clinical Trial Shows 91% Complete Remission Rate in Children with Relapsed Leukemia

Financial news for JUNO dated on 2015-04-21: Juno Therapeutics' CAR T Cell Product Candidate JCAR017 Demonstrates Continuing Encouraging Outcomes in Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

Financial news for JUNO dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for JUNO dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for JUNO dated on 2015-04-17: Analyst Points At 3 Upcoming Biotech Lock-Up Expirations

Financial news for JUNO dated on 2015-04-06: Juno Therapeutics Reports Patent Litigation Settlement

Financial news for JUNO dated on 2015-04-02: 3 Industries In A Bubble That Aren't Technology

Financial news for JUNO dated on 2015-03-25: Hearing Juno Therapeutics on Fast Money Tonight

Financial news for JUNO dated on 2015-03-18: Earnings Scheduled For March 18, 2015

Financial news for JUNO dated on 2015-02-26: Short Sellers Come Back To Biotech Stocks

Financial news for JUNO dated on 2015-02-18: Benzinga's M&A Chatter for Wednesday February 18, 2015

Financial news for JUNO dated on 2015-02-18: Hearing Unconfirmed Market Chatter of Potential Gilead Bid for Juno

Financial news for JUNO dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for JUNO dated on 2015-01-14: What Sets Juno Therapeutics Inc Apart In Immunotherapy Space?

Financial news for JUNO dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for JUNO dated on 2015-01-13: Morning Market Losers

Financial news for JUNO dated on 2015-01-13: Benzinga's Top Initiations

Financial news for JUNO dated on 2015-01-13: Benzinga's Top #PreMarket Losers

Financial news for JUNO dated on 2015-01-13: Leerink Partners Initiates Coverage on Juno Therapeutics at Outperform, Announces \$74.00 PT

Financial news for JUNO dated on 2015-01-13: JP Morgan Initiates Juno Therapeutics At Overweight

Financial news for JUNO dated on 2015-01-13: Goldman Sachs Initiates Coverage on Juno Therapeutics at Neutral, Announces \$52.00 PT

Financial news for JUNO dated on 2015-01-13: JP Morgan Initiates Coverage on Juno Therapeutics at Overweight, Announces \$66.00 PT

Financial news for JUNO dated on 2015-01-09: Benzinga's Top #PreMarket Gainers

Financial news for JUNO dated on 2014-12-29: Mid-Day Market Update: Ambarella Slips On Analyst Downgrade; Juno Therapeutics Shares Surge

Financial news for JUNO dated on 2014-12-29: Mid-Morning Market Update: Markets Edge Higher; Carl Icahn Discloses Stake In Manitowoc

Financial news for JUNO dated on 2014-12-29: Stocks Hitting 52-Week Highs

Financial news for JUNO dated on 2014-12-29: Morning Market Movers

Financial news for JUNO dated on 2014-12-29: Juno Therapeutics Surges Another 5%, Breaks Above \$50 level

Financial news for JUNO dated on 2014-12-29: Benzinga's Top #PreMarket Gainers

Financial news for JUNO dated on 2014-12-29: UPDATE: Juno Therapeutics Shares Rise 4.5% Premarket Following Release of 8-K Indicating Payment of \$20M Cash, 1.6M Shares to Opus Bio as Conditions to Satisfy License Agreement

Financial news for JUNO dated on 2014-12-29: 8-K Filing Shows Juno Therapeutics Pays \$20M Cash, 1.6M Shares To Opus Bio, Conditions To Pact Satisfied

Financial news for JUNO dated on 2014-12-26: Morning Market Movers

Financial news for JUNO dated on 2014-12-26: Benzinga's Top #PreMarket Gainers

Financial news for JUNO dated on 2014-12-23: Benzinga's Top #PreMarket Losers

Financial news for JUNO dated on 2014-12-19: Shares of Juno Therapeutics Open for Trade at \$39/Share, IPO Priced at \$24

Financial news for JUNO dated on 2014-12-19: Expected IPOs For December 19

Financial news for JUNO dated on 2014-12-19: PREVIEW: Juno Therapeutics IPO Expected to Open at 10:25 AM ET

Financial news for JUNO dated on 2014-12-18: Athersys Shares Move Higher Ahead of Friday JUNO IPO

Financial news for JUNO dated on 2014-12-16: Amended S-1 Filing from Juno Therapeutics Shows Increased IPO Price Range from \$15-\$18/Share Previously to \$21-\$23/Share

Financial news for JUNO dated on 2014-12-09: Juno Therapeutics Expects 9.3M Share IPO to Price \$15.00-\$18.00/Share

Financial news for JUNO dated on 2014-11-17: Juno Therapeutics Files for up to \$150M IPO